Amy McBride Wendell sold $1.3M of AXGN
director at Axogen, Inc.. 43,684 shares at an average of $29.31, traded Dec 16, 2025, filed Dec 17, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001400568-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | MOption exercise Common Stock | +5,000 | $8.95 | $45k | 98,826 | Dec 17, 2025 |
| Dec 16, 2025 | MOption exercise Common Stock | +20,436 | $6.30 | $129k | 119,262 | Dec 17, 2025 |
| Dec 16, 2025 | MOption exercise Common Stock | +18,248 | $7.04 | $128k | 137,510 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -5,000 | $29.31 | $147k | 132,510 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -20,436 | $29.31 | $599k | 112,074 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -18,248 | $29.31 | $535k | 93,826 | Dec 17, 2025 |
| Dec 16, 2025 | MOption exercise Stock Option (right to purchase)derivative | -5,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 16, 2025 | MOption exercise Stock Option (right to purchase)derivative | -20,436 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 16, 2025 | MOption exercise Stock Option (right to purchase)derivative | -18,248 | $0.00 | $0 | 0 | Dec 17, 2025 |
Related signals
Other insiders at Axogen, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Axogen, Inc. | Joseph A. Tyndall director | $174k 3,500 shares | -25% | |
| 49Moderate | Axogen, Inc. | Lindsey Marie Hartley CFO | $442k 14,812 shares | -32% | |
| 60Notable | Axogen, Inc. | Kathy Johnson Weiler director | $1.4M 46,653 shares | -100% | |
| 56Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $397k 13,222 shares | -42% | |
| 72Notable | Axogen, Inc. | Michael D Dale Chief Executive Officer | $750k 25,000 shares | -28% | |
| 49Moderate | Axogen, Inc. | Lindsey Marie Hartley CFO | $454k 14,387 shares | -31% | |
| 70Notable | Axogen, Inc. | Paul Thomas director | $634k 21,399 shares | -61% | |
| 49Moderate | Axogen, Inc. | Marc A Began EVP & General Counsel | $290k 9,278 shares | -23% | |
| 48Moderate | Axogen, Inc. | Jens Kemp Chief Marketing Officer | $255k 8,156 shares | -15% | |
| 50Moderate | Axogen, Inc. | Erick Wayne DeVinney Chief Innovation Officer | $609k 19,517 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.